NCT05621031

Effects of Whole Body Vibration in Parkinson's Disease Symptoms

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: University of Seville · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to know the effects of an intervention in Parkinson's disease symptoms. The main question it aims to answer are: * Is whole body vibration able to reduce rigidity in Parkinson's participants? * Can whole body vibration modify gait abilities and other Parkinson's symptoms? Participants (subjects with Parkinson's disease) will do habitual therapy treatment. Experimental group will also carry out whole body vibration sessions and control group will do placebo whole body vibration sessions.

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DEVICE	Whole body Vibration	Whole body vibration will be administered with a vibration platform (Power Plate Move). Subjects will do several exercises (squats and steps) whilst on the platform, set at these parameters: frequency 30 Hz; amplitude: 2 mm; 1 min activation; 1 min rest, 5 activations. 15 sessions will be carried out (2/week).
OTHER	Habitual Therapy	Physical therapy will be administered to all study subjects. Experimental group will perform their session the same day that the experimental intervention.
DEVICE	Placebo whole body vibration	Placebo whole body vibration will be administered with a vibration platform (Power Plate Move). Subjects will do several exercises (squats and steps) whilst on the platform. The platform will only be working for 3 seconds (parameters: frequency 30 Hz; amplitude: 2 mm) and after 3 seconds, the vibration will stop. Same as experimental group, there will be 1 min placebo activation; 1 min rest, 5 activations. 15 sessions will be carried out (2/week).

Timeline

• Start date: 2023-01-01
• Primary completion: 2023-09-30
• Completion: 2023-11-30
• First posted: 2022-11-17
• Last updated: 2022-11-17

Locations

1 site across 1 country: Spain

Regulatory

• FDA-regulated device study